Cover Image
市場調查報告書

眼瞼炎:開發中產品分析

Blepharitis - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 200931
出版日期 內容資訊 英文 53 Pages
訂單完成後即時交付
價格
Back to Top
眼瞼炎:開發中產品分析 Blepharitis - Pipeline Review, H2 2017
出版日期: 2017年08月22日 內容資訊: 英文 53 Pages
簡介

眼瞼炎是指眼皮發炎。一般是在皮膚上普遍存在的細菌過度繁殖,或是眼皮的皮脂腺堵塞等,都是眼臉炎發病的要因,但各種過敏症也有可能導致發病。瞼炎的症狀有眼睛流淚發紅,眼皮發癢,畏光等。主要的治療方法有抗生素和眼藥,類固醇眼藥、軟膏等。

本報告提供全球各國治療眼瞼炎所用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要 (標的,作用機制,投藥途徑,許可證/產業強力體制等),最新的產業趨勢等調查結果。

目錄

簡介

  • 分析範圍

眼瞼炎概要

治療藥的開發

  • 眼瞼炎開發中產品:概要
  • 眼瞼炎開發中產品:比較分析

各企業開發中的眼瞼炎治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

眼瞼炎治療藥:開發中的產品一覽 (各企業)

眼瞼炎開發治療藥的企業

  • Allergan Plc
  • InSite Vision Incorporated
  • Kala Pharmaceuticals, Inc.
  • NicOx S.A.
  • Quorum Innovations LLC
  • 千壽製藥

眼瞼炎:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各行動機制
  • 各投藥法
  • 各分子類型

藥物簡介

眼瞼炎治療藥:開發暫停的產品

眼瞼炎相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9663IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Blepharitis - Pipeline Review, H2 2017, provides an overview of the Blepharitis (Ophthalmology) pipeline landscape.

Blepharitis is an inflammation of the eyelids, usually caused by an excess growth of bacteria that is ordinarily found on the skin, blockage of the eyelid's oil glands, and occasionally allergies. Blepharitis signs and symptoms include watery eyes, red eyes, itchy eyelids, sensitivity to light. Treatment includes antibiotics, lubricating eye drops and steroid eye drops or ointments.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Blepharitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Blepharitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Blepharitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Blepharitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 1 and 5 respectively.

Blepharitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Blepharitis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Blepharitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Blepharitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Blepharitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Blepharitis (Ophthalmology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Blepharitis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Blepharitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Blepharitis - Overview
    • Blepharitis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Blepharitis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Blepharitis - Companies Involved in Therapeutics Development
    • Hovione FarmaCiencia SA
    • InSite Vision Inc
    • Kala Pharmaceuticals Inc
    • Marinomed Biotechnologie GmbH
    • Merck & Co Inc
    • NicOx SA
    • Quorum Innovations LLC
  • Blepharitis - Drug Profiles
    • azithromycin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dexamethasone acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fluticasone propionate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ISV-405 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • loteprednol etabonate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Qi-402 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Blepharitis and Conjunctivitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • solithromycin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tetracycline - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Blepharitis - Dormant Projects
  • Blepharitis - Product Development Milestones
    • Featured News & Press Releases
      • Jan 05, 2017: Nicox provides clinical and regulatory update for NCX 4251 in blepharitis
      • Jul 08, 2014: InSite Vision Plans to Submit New Drug Application to FDA for DexaSite for the Treatment of Blepharitis in Adults
      • Nov 12, 2013: Kala Pharmaceuticals Presents Preclinical Data on Mucus Penetrating Particles at 2013 AAPS Annual Meeting and Exposition
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Blepharitis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Blepharitis - Pipeline by Hovione FarmaCiencia SA, H2 2017
  • Blepharitis - Pipeline by InSite Vision Inc, H2 2017
  • Blepharitis - Pipeline by Kala Pharmaceuticals Inc, H2 2017
  • Blepharitis - Pipeline by Marinomed Biotechnologie GmbH, H2 2017
  • Blepharitis - Pipeline by Merck & Co Inc, H2 2017
  • Blepharitis - Pipeline by NicOx SA, H2 2017
  • Blepharitis - Pipeline by Quorum Innovations LLC, H2 2017
  • Blepharitis - Dormant Projects, H2 2017

List of Figures

  • Number of Products under Development for Blepharitis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top